Media & Investors
Transparency is important to us. Find important information about Kuros Biosciences here – from our corporate documents to our current share price.
01 Sep 2020
Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PTH
Reports & corporate governance
Kuros Biosciences is fully committed to good corporate governance and adherence to high ethical standards. Our principles and rules on corporate governance and ethical conduct are articulated in the Articles of Association, the Internal Regulations, the charters of the committees of our board of directors, and our code of conduct.
Olav Zilian, MD, PhD, EMBA
Mirabaud Securities Ltd
David Sherman, Ph.D.(AC)
Please use the button below to view and download Analyst reports
|Mar 26, 2020||Kuros will publish its Annual Report for 2019|
|Apr 21, 2020||Kuros will hold its Annual Shareholders' Meeting|
|Aug 12, 2020||Kuros will publish its Half Year Report for H1 2020|